We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Nanoscale X-Ray Technique Devised for Imaging of Bacterial Cells

By LabMedica International staff writers
Posted on 19 Jan 2010
An ultra-high resolution imaging technique using X-ray diffraction is one step closer to fulfilling its potential as a window into nanometer-scale structures in biologic samples. More...


In research published December 17, 2009, in the online issue of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS), researchers reported progress in applying an approach to "lensless” X-ray microscopy, which they introduced one year ago. They have produced the first images, using this technique, of biologic cells--specifically the fascinating polyextremophile Deinococcus radiodurans.

Improved ability to see nanoscale structures in cells could provide significant insights for evolutionary biology and biotechnology. In the case of D. radiodurans, for example, it could help to answer questions about whether--or how--the structure of this organism's DNA-bearing nucleoid region accounts for its stamina against ionizing radiation. Having demonstrated the resolution, effectiveness, and reproducibility of their technique, the researchers are now working to extend it to three-dimensional (3D) imaging of biologic cells.

X-ray imaging is best known for its medical applications, such as conventional radiographs and computed tomography (CT) scans. However, the use of X-rays goes far beyond standard imaging. In particular, the very short wavelength of X-ray radiation allows various modes of microscopy that can reach the nanometer resolution. One of the major obstacles to high-resolution X-ray microscopy is the difficulty of producing high-quality X-ray lenses. To overcome these difficulties, so-called lensless microscopy methods have emerged in the last decade. A technique developed by researchers now in the biomedical physics group from the Technische Universitaet Muenchen (TUM; Munich. Germany) has shown great promise for ultra-high resolution imaging of materials and life science samples.

This imaging technique, called ptychography, was first introduced in the 1970s for electron diffraction. It consists in measuring full far-field diffraction patterns as a small illumination is scanned on a sample. While its use in electron microscopy is still limited, ptychography has gained tremendous popularity in the X-ray imaging community in the last few years, due to the development by Franz Pfeiffer, now chair of the biomedical physics group at TUM, and his team. A critical step in the development of ptychography was published by the team one year ago and published in the August 15, 2009, issue of the journal Science. The super-resolution capability of the imaging method was successfully demonstrated with a gold test structure.

Now a collaboration of the Pfeiffer group, together with researchers from the University of Gottingen (Germany) and at the Swiss Light Source (Villigen, Switzerland), has gone a step further and produced the first images of biologic cells with the same technique.

These study findings demonstrated that lensless X-ray imaging, specifically ptychography, could be used to obtain precise maps of the electron density forming a biologic sample. This type of quantitative measurement is extremely difficult with most other high-resolution techniques currently available. Moreover, biologic samples are very fragile and nearly transparent to X-rays, making this type of accurate measurement even more challenging.

The Pfeiffer group is now moving beyond this achievement and looking into ways of additionally improving the technique. In particular, the team is aiming at the next milestone: 3D imaging of biologic samples.

Related Links:

Technische Universitaet Muenchen
University of Gottingen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.